Physician profile
Amy Beard
NPI 1598425670
$6,036.18
in general payments reported to CMS, 2019-2025
23 companies · $1,914 in 2025
The $1,914 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $858 · 2023: $2,130 · 2024: $1,134 · 2025: $1,914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,442 · Travel and Lodging: $709 · Education: $27.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,441.59 |
| Travel and Lodging | $709.37 |
| Education | $27.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,532.01 | 2022-2025 | |
| Medtronic, INC. | $883.19 | 2023-2024 | Interstim |
| Gilead Sciences, INC. | $494.91 | 2022-2025 | Livdelzi, Epclusa |
| Ardelyx, INC. | $359.75 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $351.56 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $251.26 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $171.66 | 2022-2025 | Gattex, Entyvio |
| Intercept Pharmaceuticals, INC. | $167.52 | 2022-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $146.32 | 2022-2024 | Linzess |
| Lilly USA, LLC | $118.77 | 2024-2025 | Omvoh |
| Celgene Corporation | $108.79 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $82.46 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $61.30 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $58.50 | 2023-2025 | Dupixent |
| Genzyme Corporation | $56.39 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $39.66 | 2024 | |
| Aimmune Therapeutics, INC. | $36.44 | 2025 | Zenpep |
| Mallinckrodt Hospital Products INC. | $24.61 | 2022 | |
| Evoke Pharma, INC. | $24.48 | 2023 | Gimoti |
| Merck Sharp & Dohme LLC | $18.17 | 2022 | |
| Braintree Laboratories, INC. | $17.60 | 2023 | Suflave |
| Fresenius Kabi USA, LLC | $16.01 | 2023 | Idacio |
| Novo Nordisk INC | $14.82 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Beard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.